ON THE ISSUE OF EXPANDING THE INDICATIONS OF THE USE OF AN IMMUNOMODULATING DRUG IN THE TREATMENT AND PREVENTION OF INFLUENZA AND ACUTE RESPIRATORY INFECTIONS IN YOUNG CHILDREN

Abstract

The data on the safety and effectiveness of the use of the domestic immunomodulating preparation Polyoxidonium® (azoximer bromide) in children are summarized in the following pages. Polyoxidonium has an immunomodulatory (including interferon-inducing), detoxication and anti-inflammatory effect that allows the clinical course of the disease to be quickly alleviated and the natural immune response modulated. The clinical effectiveness of the drug in acute respiratory infections (ARI) in children, including those with allergic anamnesis. Recent studies have proven the effectiveness of the 7-day course of the preparation Polyoxidonium® for the treatment and prevention of ARI and influenza in children, starting at the age of 3 years, as evidenced by a rapid positive dynamics of clinical symptoms and a 2-fold decrease in ARI frequency compared to placebo group at 6 months after the end of therapy.

Keywords

• acute respiratory infections (ari)
• azoximer bromide
• polyoxidonium®
• immunomodulator
• children